MARKET

NVIV

NVIV

InVivo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6086
-0.0114
-1.84%
Closed 18:47 09/16 EDT
OPEN
0.6309
PREV CLOSE
0.6200
HIGH
0.6480
LOW
0.6086
VOLUME
339.53K
TURNOVER
--
52 WEEK HIGH
2.000
52 WEEK LOW
0.4975
MARKET CAP
20.85M
P/E (TTM)
-0.8258
1D
5D
1M
3M
1Y
5Y
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference
CAMBRIDGE, Mass., September 09, 2021--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D.,...
Business Wire · 09/09 12:00
BRIEF-Invivo Says 75% Target Enrollment Achieved For Inspire 2.0 Spinal Cord Injury Study
reuters.com · 09/08 12:22
InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has enrolled 15 patients with acute spinal cord injury in...
Business Wire · 09/08 12:00
InVivo Therapeutics Reaches 75% of Enrollment Target for Spinal Cord Injury Study
MT Newswires · 09/08 08:48
25 Stocks Moving in Monday's Pre-Market Session
Gainers
Benzinga · 08/23 11:00
Top Premarket Gainers
MT Newswires · 08/20 08:18
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers
Benzinga · 07/29 16:39
BioFlyte Forms Scientific Advisory Board of Prominent Government and Life Science Experts
BioFlyte, a biodetection company with a revolutionary new class of fieldable biological threat collection, detection, and identification solutions, today announced the formation of a Scientific Advisory Board (SAB). The SAB is comprised of seven accomplish...
Business Wire · 07/27 13:00
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVIV. Analyze the recent business situations of InVivo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS
Institutional Holdings
Institutions: 40
Institutional Holdings: 2.58M
% Owned: 7.53%
Shares Outstanding: 34.26M
TypeInstitutionsShares
Increased
7
267.43K
New
3
257.85K
Decreased
6
254.23K
Sold Out
5
149.85K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.49%
Healthcare Equipment & Supplies
-0.15%
Key Executives
Non-Executive Chairman/Independent Director
C. Ann Merrifield
President/Chief Executive Officer/Director
Richard Toselli
Chief Financial Officer
Richard Christopher
Independent Director
Daniel Marshak
Independent Director
Christina Morrison
Independent Director
Richard Roberts
Independent Director
Robert Rosenthal
No Data
  • All
  • Financials
  • Insiders
More
About NVIV
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Webull offers kinds of Invivo Therapeutics Holdings Corp stock information, including NASDAQ:NVIV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVIV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVIV stock methods without spending real money on the virtual paper trading platform.